S&P 500:  2,857.05  +6.92 (+0.24%)
DOW:  25,758.69  +89.37 (+0.35%)
NASDAQ:  7,821.01  +4.68 (+0.06%)

NYSE:ZBH - Zimmer Biomet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Get Started
$124.67 +0.81 (+0.65 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$123.86
Today's Range$123.88 - $124.92
52-Week Range$104.28 - $129.34
Volume702,400 shs
Average Volume1.20 million shs
Market Capitalization$24.94 billion
P/E Ratio15.54
Dividend Yield0.78%
Beta1.13
Zimmer Biomet logoZimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZBH
CUSIPN/A
Webwww.zimmerbiomet.com
Phone574-267-6131

Debt

Debt-to-Equity Ratio0.78
Current Ratio2.41
Quick Ratio1.25

Price-To-Earnings

Trailing P/E Ratio15.54
Forward P/E Ratio16.25
P/E Growth2.23

Sales & Book Value

Annual Sales$7.82 billion
Price / Sales3.24
Cash Flow$15.2222 per share
Price / Cash8.19
Book Value$57.96 per share
Price / Book2.15

Profitability

EPS (Most Recent Fiscal Year)$8.03
Net Income$1.81 billion
Net Margins21.67%
Return on Equity13.53%
Return on Assets5.95%

Miscellaneous

Employees18,200
Outstanding Shares203,490,000
Market Cap$24.94 billion

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Thursday, June 14th. Stockholders of record on Friday, June 29th will be paid a dividend of $0.24 per share on Tuesday, July 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date is Thursday, June 28th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) posted its quarterly earnings data on Friday, July, 27th. The medical equipment provider reported $1.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $0.04. The medical equipment provider earned $2.01 billion during the quarter, compared to the consensus estimate of $1.99 billion. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. The firm's revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.08 earnings per share. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet updated its FY18 earnings guidance on Friday, July, 27th. The company provided EPS guidance of $7.60-7.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.64. The company issued revenue guidance of $7.90-8.02 billion, compared to the consensus revenue estimate of $7.98 billion.

What price target have analysts set for ZBH?

25 equities research analysts have issued 1-year price targets for Zimmer Biomet's stock. Their predictions range from $96.00 to $168.00. On average, they expect Zimmer Biomet's share price to reach $135.4286 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 8 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. Needham & Company LLC analysts commented, "We are downgrading ZBH to Buy from Strong Buy. Our downgrade is due to reduced growth potential given slower orthopedic market growth, the need for portfolio management to drive higher revenue growth (which we expect to take significant time), ZBH’s need for reinvestment which is likely to weigh on its margins, and ZBH’s valuation." (8/13/2018)
  • 2. According to Zacks Investment Research, "In the past six months, Zimmer Biomet has been observed to underperform its industry. The year-over-year decline in earnings and revenues in the last reported quarter made investors jittery.  Declining sales at Knees, Hips and other segments at CER were a major disappointment. According to the company, slower pace of supply recovery and sales recapture related to major brands within the company’s Knee, Hip and S.E.T. segments marred the quarterly performance. Also, escalating costs and expenses impacted margins.  On the bright side, the company’s consistent efforts in product and renovation through research and development raise hopes. We are optimistic about synergies from the LDR buyout as well. We are also impressed by the strategic and financial goals which the combined entity expects to reach." (7/17/2018)
  • 3. Canaccord Genuity analysts commented, "We are updating our model to reflect Zimmer’s adoption of several previously disclosed new accounting standards (revenue recognition for customer contracts, reporting of pension costs, and hedging activities). The company adopted the changes effective January 1, 2018, and recently provided updated historical financials (for 2016 and 2017) to reflect a retrospective adoption of the new standards. While the new accounting policies have not resulted in any material changes to 2016 and 2017 historical results, we have nonetheless updated our model to reflect how the company will report moving forward. Additionally, we have also tweaked our forward estimates to incorporate a slightly more conservative revenue ramp in 2018/2019 and higher COGS and operating spend related to the quality/manufacturing remediation and sales channel incentives/ investments. Thus we maintain our HOLD rating and lower our price target to $121." (4/12/2018)
  • 4. Cantor Fitzgerald analysts commented, "ZBH received FDA clearance for its Persona cementless knee, earlier than we expected." (2/5/2018)

Who are some of Zimmer Biomet's key competitors?

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 56)
  • Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics

Has Zimmer Biomet been receiving favorable news coverage?

Press coverage about ZBH stock has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 45.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Zimmer Biomet.

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.53%), Massachusetts Financial Services Co. MA (7.15%), Longview Partners Guernsey LTD (3.81%), American Century Companies Inc. (2.39%), FMR LLC (1.22%) and Bank of New York Mellon Corp (1.18%). Company insiders that own Zimmer Biomet stock include Bryan C Hanson, Chad F Phipps, Daniel E Williamson, David A Jr Nolan, David C Dvorak, Katarzyna Mazur-Hofsaess, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Hexavest Inc., FMR LLC, American Century Companies Inc., Bank of Montreal Can, Russell Investments Group Ltd. and Summit Trail Advisors LLC. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Renaissance Technologies LLC, State of New Jersey Common Pension Fund D, Voya Investment Management LLC, Morgan Stanley, First Trust Advisors LP, Sei Investments Co. and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $124.67.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $24.94 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  626 (Vote Outperform)
Underperform Votes:  522 (Vote Underperform)
Total Votes:  1,148
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Featured Article: Why Dividend Stocks May Be Right for You
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel